DHI
48
4
STZ
54
-3
NEE
50
-5
ROST
63
12
NWS
66
-3
HP
48
3
PLD
56
8
TROW
56
5
PSX
47
2
LRCX
43
-2
UA
50
-9
PFG
45
3
SIG
52
3
MCHP
41
4
MPC
44
-3
HCA
44
-2
RIG
60
2
HRB
57
5
CSX
60
3
GPC
40
3
DHI
48
4
STZ
54
-3
NEE
50
-5
ROST
63
12
NWS
66
-3
HP
48
3
PLD
56
8
TROW
56
5
PSX
47
2
LRCX
43
-2
UA
50
-9
PFG
45
3
SIG
52
3
MCHP
41
4
MPC
44
-3
HCA
44
-2
RIG
60
2
HRB
57
5
CSX
60
3
GPC
40
3
Financhill
Back

Matinas BioPharma Holdings 10K Form

Sell
38

MTNB
Matinas BioPharma Holdings

Last Price:
0.63
Seasonality Move:
10.6%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive MTNB News And Ratings

See the #1 stock for the next 7 days that we like better than MTNB

MTNB Financial Statistics

Sales & Book Value

Annual Sales: $1.1M
Cash Flow: $-3.5M
Price / Cash Flow: 0
Annual Sales: $3.10
Price / Book: 0.2

Profitability

EPS (TTM): -4.79000
Net Income (TTM): $-21.13M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Matinas BioPharma Holdings Earnings Forecast

Key Matinas BioPharma Holdings Financial Ratios

  • The Research & Development expenses have been 1,321.99% of Revenue.
  • The Net Earning history of MTNB is -2,093.25% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

Matinas BioPharma Holdings Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Biotechnology
Sector: Health Care
Current Symbol: MTNB
Website: matinasbiopharma.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

MTNB Technical Analysis vs Fundamental Analysis

Sell
38
Matinas BioPharma Holdings (MTNB) is a Sell

Is Matinas BioPharma Holdings a Buy or a Sell?